Abrams, J.A., Kapel, R.C., Lindberg, G.M., Saboorian, M.H., Genta, R.M., Neugut, A.I. et al. (2009) Adherence to biopsy guidelines for Barrett s esophagus surveillance in the community setting in the United States, Clin Gastroenterol Hepatol (in press).
2.
Amamra, N., Touzet, S., Colin, C. and Ponchon, T. (2007) Current practice compared with the international guidelines: endoscopic surveillance of Barrett's esophagus, J Eval Clin Pract13: 789-794.
3.
Badreddine, R. and Wang, K.K. (2008) Biomarkers in gastrointestinal cancers, Am J Gastroenterol103: 2106-2610.
4.
Brown, L.M., Devesa, S.S. and Chow, W.H. (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age, J Natl Cancer Inst100: 1184-1187.
5.
Cameron, A.J., Zinsmeister, A.R., Ballard, D.J. and Carney, J.A. (1990) Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings, Gastroenterology99: 918-922.
6.
Conio, M., Blanchi, S., Lapertosa, G., Ferraris, R., Sablich, R., Marchi, S. et al. (2003) Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study, Am J Gastroenterol98: 1931-1939.
7.
Conio, M., Cameron, A.J., Romero, Y., Branch, C.D., Schleck, C.D., Burgart, L.J. et al. (2001) Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota, Gut48: 304-309.
8.
Corley, D.A., Kerlikowske, K., Verma, R. and Buffler, P. (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis, Gastroenterology124: 47-56.
9.
Corley, D.A., Levin, T.R., Habel, L.A., Weiss, N.S. and Buffler, P.A. (2002) Surveillance and survival in Barrett's adenocarcinomas: a population-based study, Gastroenterology122: 633-640.
10.
Das, D., Ishaq, S., Harrison, R., Kosuri, K., Harper, E., Decaestecker, J. et al. (2008) Management of Barrett's esophagus in the UK: Overtreated and underbiopsied but improved by the introduction of a national randomized trial, Am J Gastroenterol103: 1079-89.
11.
Drewitz, D.J., Sampliner, R.E. and Garewal, H.S. (1997) The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years, Am J Gastroenterol92: 212-215.
12.
El-Serag, H.B., Aguirre, T.V., Davis, S., Kuebeler, M., Bhattacharyya, A. and Sampliner, R.E. (2004a) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus, Am J Gastroenterol99: 1877-1883.
13.
El-Serag, H.B., Petersen, N.J., Carter, J., Graham, D.Y., Richardson, P., Genta, R.M. et al. (2004b) Gastroesophageal reflux among different racial groups in the United States, Gastroenterology126: 1692-1699.
14.
Falk, G.W., Ours, T.M. and Richter, J.E. (2000) Practice patterns for surveillance of Barrett's esophagus in the united states, Gastrointest Endosc52: 197-203.
15.
Fleischer, D.E., Overholt, B.F., Sharma, V.K., Reymunde, A., Kimmey, M.B., Chuttani, R. et al. (2008) Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up, Gastrointest Endosc68: 867-876.
16.
Garcia Rodriguez, L.A., Lagergren, J. and Lindblad, M. (2006) Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK, Gut55: 1538-1544.
17.
Jankowski, J. and Moayyedi, P. (2004) Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus, J Natl Cancer Inst96: 885-887; author reply 887.
18.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. et al. (2008) Cancer statistics, 2008, CA Cancer J Clin58: 71-96.
19.
Lepage, C., Rachet, B., Jooste, V., Faivre, J. and Coleman, M.P. (2008) Continuing rapid increase in esophageal adenocarcinoma in England and Wales, Am J Gastroenterol103: 2694-2699.
20.
Mandal, A., Playford, R.J. and Wicks, A.C. (2003) Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK, Aliment Pharmacol Ther17: 1319-1324.
21.
Montgomery, E., Bronner, M.P., Goldblum, J.R., Greenson, J.K., Haber, M.M., Hart, J. et al. (2001) Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation, Hum Pathol32: 368-378.
22.
Ofman, J.J., Shaheen, N.J., Desai, A.A., Moody, B., Bozymski, E.M. and Weinstein, W.M. (2001) The quality of care in Barrett's esophagus: endoscopist and pathologist practices, Am J Gastroenterol96: 876-881.
23.
Overholt, B.F., Lightdale, C.J., Wang, K.K., Canto, M.I., Burdick, S., Haggitt, R.C. et al. (2005) Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial, Gastrointest Endosc62: 488-498.
24.
Prasad, G.A., Wang, K.K., Buttar, N.S., Wongkeesong, L.M., Krishnadath, K.K., Nichols 3rd F.C. et al. (2007) Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus, Gastroenterology132: 1226-1233.
25.
Prasad, G.A., Wang, K.K., Halling, K.C., Buttar, N.S., Wongkeesong, L.M., Zinsmeister, A.R. et al. (2008) Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus, Gastroenterology135: 370-379.
26.
Rex, D.K., Cummings, O.W., Shaw, M., Cumings, M.D., Wong, R.K., Vasudeva, R.S. et al. (2003) Screening for Barrett's esophagus in colonoscopy patients with and without heartburn, Gastroenterology125: 1670-1677.
27.
Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S.E., Lind, T., Bolling-Sternevald, E. et al. (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study, Gastroenterology129: 1825-1831.
28.
Sampliner, R.E. (1998) Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology, Am J Gastroenterol93: 1028-1032.
29.
Shaheen, N.J., Sharma, P., Overholt, B.F., Lightdale, C.J., Wolfsen, H.C., Sampliner, R.E. et al. (2008) A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for Subjects with Barrett's esophagus (BE) containing dysplasia: Interim results of the AIM Dysplasia Trial, Gastroenterology134: A37.
30.
van Sandick, J.W., Bartelsman, J.F., van Lanschot, J.J., Tytgat, G.N. and Obertop, H. (2000) Surveillance of Barrett's oesophagus: physicians' practices and review of current guidelines, Eur J Gastroenterol Hepatol12: 111-117.
31.
Vaughan, T.L., Dong, L.M., Blount, P.L., Ayub, K., Odze, R.D., Sanchez, C.A. et al. (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study , Lancet Oncol6: 945-952.
32.
Wang, K.K. and Sampliner, R.E. (2008) Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus, Am J Gastroenterol103: 788-797.
